ChiCTR2500109671 版本V1.0 版本创建时间2025/09/23 17:16:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500109671 

最近更新日期:

Date of Last Refreshed on:

2025-09-23 17:16:11 

注册时间:

Date of Registration:

2025-09-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

全麻剖宫产术中使用小剂量艾司氯胺酮对产妇产后抑郁的疗效:一项双中心、前瞻性随机对照研究

Public title:

Effect of low-dose esketamine on postpartum depression in women undergoing general anesthesia for cesarean delivery: a dual-center, prospective, randomized controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

全麻剖宫产术中使用小剂量艾司氯胺酮对产妇产后抑郁的疗效:一项双中心、前瞻性随机对照研究

Scientific title:

Effect of low-dose esketamine on postpartum depression in women undergoing general anesthesia for cesarean delivery: a dual-center, prospective, randomized controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周双琼 

研究负责人:

曹秀红 

Applicant:

Zhou Shuanqiong 

Study leader:

Cao Xiuhong 

申请注册联系人电话:

Applicant telephone:

+86 139 1617 4158

研究负责人电话:

Study leader's
telephone:

+86 139 1859 6527

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zsq628628@163.com

研究负责人电子邮件:

Study leader's E-mail:

caoxiuhong@51mch.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海浦东新区高科西路2699号

研究负责人通讯地址:

上海浦东新区高科西路2699号

Applicant address:

2699 Gaoke Road West, Pudong New Area, Shanghai

Study leader's address:

2699 Gaoke Road West, Pudong New Area, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第一妇婴保健院

Applicant's institution:

Shanghai First Maternity and Infant Hospital

研究负责人所在单位:

上海市第一妇婴保健院

Affiliation of the Leader:

Shanghai First Maternity and Infant Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KS25181

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第一妇婴保健院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shanghai First Maternity and Infant Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-04-23 00:00:00

伦理委员会联系人:

李春林

Contact Name of the ethic committee:

Li Chunlin

伦理委员会联系地址:

上海市浦东新区高科西路2699号

Contact Address of the ethic committee:

2699 Gaoke Road West, Pudong New Area, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 2026 1211

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第一妇婴保健院

Primary sponsor:

Shanghai First Maternity and Infant Hospital

研究实施负责(组长)单位地址:

上海市浦东新区高科西路2699号

Primary sponsor's address:

2699 Gaoke Road West, Pudong New Area, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第一妇婴保健院

具体地址:

上海市浦东新区高科西路2699号

Institution
hospital:

Shanghai First Maternity and Infant Hospital

Address:

2699 Gaoke Road West, Pudong New Area, Shanghai

经费或物资来源:

院级课题经费

Source(s) of funding:

Hospital-Level Research Project Funding

研究疾病:

产后抑郁  

Target disease:

postpartum depression

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

我们研究团队计划开展一项前瞻性随机对照试验,以接受全麻下行剖宫产终止妊娠的母亲为研究对象,通过收集围产期数据及产后3个月的随访数据,评估术中静脉泵注艾司氯胺酮是否可以降低孕产妇产后抑郁的发生率。  

Objectives of Study:

Our research team plans to conduct a prospective randomized controlled trial focusing on mothers undergoing cesarean delivery under general anesthesia. By collecting perinatal data and follow-up data at three months postpartum, we aim to evaluate whether intraoperative intravenous infusion of esketamine can reduce the incidence of postpartum depression in parturients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄>=18岁 2.美国麻醉医师协会(ASA)分级II至 Ⅲ; 3.单胎妊娠; 4.足月(>=37周)妊娠; 5. 计划在全麻下行择期剖宫产。

Inclusion criteria

1. Age>=18 years old 2. American Society of Anesthesiologists (ASA) grade II to III; 3. Singleton pregnancy; 4. Term (>=37 weeks) pregnancy; 5. Planned elective cesarean section under general anesthesia.

排除标准:

1.产前有精神障碍性疾病; 2.精神类药物应用史; 3.严重的产科合并症:如子痫前期和子痫、妊娠高血压、颅内高压、甲状腺功能亢进、前置胎盘或胎盘早剥等; 4.严重产科并发症:如术中失血>1000 ml、合并脏器损伤(肠道或泌尿系统损伤)等; 5.对NMDA受体拮抗剂过敏; 6.术前低血压(定义为收缩压<90 mmHg); 7.拒绝使用术后镇痛泵;不愿意配合问卷调查和临床检查者。

Exclusion criteria:

1. Prenatal mental disorders; 2. History of psychotropic drug use; 3. Severe obstetric comorbidities: such as preeclampsia and eclampsia, gestational hypertension, intracranial hypertension, hyperthyroidism, placenta previa or placental abruption, etc.; 4. Serious obstetric complications: such as intraoperative blood loss >1000 ml, combined organ damage (intestinal or urinary system injury), etc.; 5. Allergy to NMDA receptor antagonists; 6. Preoperative hypotension (defined as systolic blood pressure <90 mmHg); 7. Refusal to use postoperative analgesic pumps; Unwilling to cooperate with questionnaires and clinical examinations.

研究实施时间:

Study execute time:

From 2025-10-01 00:00:00 To 2027-10-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-10-01 00:00:00 To 2027-10-01 00:00:00

干预措施:

Interventions:

组别:

艾司氯胺酮组

样本量:

150

Group:

esketamine group

Sample size:

干预措施:

胎儿娩出后,艾司氯胺酮(ESK)组:艾司氯胺酮0.2 mg/kg,加入到20 ml生理盐水中泵注40分钟,泵速30 ml/h;术后采用患者自控镇痛,包含:艾司氯胺酮50mg+舒芬太尼100 μg+托烷司琼10 mg,用生理盐水稀释到100 ml入泵。术后泵设置为持续输注2 ml/h,持续输注48小时,Bolus剂量2 ml,锁定时间10分钟。

干预措施代码:

Intervention:

In the Esketamine (ESK) group, after fetal delivery:Esketamine at 0.2 mg/kg was added to 20 ml of normal saline and infused via pump over 40 minutes at a pump rate of 30 ml/h.At the end of surgery, patient-controlled intravenous analgesia (PCIA) was initiated for each patient. The formula of PCIA contained esketamine 50 mg , sufentanil 100 μg and tropisetron 10 mg, dissolved in saline to a 100-mL solution. PCIA was programmed for continuous infusion at 2mL per hour with a bolus dose of 2mL,allowed every 10 minutes.

Intervention code:

组别:

对照组

样本量:

150

Group:

Control

Sample size:

干预措施:

胎儿娩出后,对照组输注20 ml生理盐水中,泵注40分钟,泵速30 ml/h;术后采用患者自控镇痛,包含:舒芬太尼100 μg+托烷司琼10 mg,用生理盐水稀释到100 ml入泵。术后泵设置为持续输注2 ml/h,持续输注48小时,Bolus剂量2 ml,锁定时间10分钟。

干预措施代码:

Intervention:

In the Control group, after fetal delivery: 20 ml normal saline was infused via pump over 40 minutes at a pump rate of 30 ml/h.At the end of surgery, patient-controlled intravenous analgesia (PCIA) was initiated for each patient. The formula of PCIA contained sufentanil 100 μg and tropisetron 10 mg, dissolved in saline to a 100-mL solution. PCIA was programmed for continuous infusion at 2mL per hour with a bolus dose of 2mL,allowed every 10 minutes.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第一妇婴保健院 

单位级别:

三甲 

Institution
hospital:

Shanghai First Maternity and Infant Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

福建 

市(区县):

泉州 

Country:

China

Province:

Fujian

City:

Quanzhou

单位(医院):

泉州妇幼保健院·儿童医院 

单位级别:

三甲 

Institution
hospital:

Quanzhou Women's and Children's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

抑郁发生率

指标类型:

主要指标

Outcome:

Incidence of postpartum depression

Type:

Primary indicator

测量时间点:

产后7天

测量方法:

Measure time point of outcome:

at 7 days

Measure method:

指标中文名:

抑郁的发生率

指标类型:

次要指标

Outcome:

Incidence of postnatal depression

Type:

Secondary indicator

测量时间点:

产后42天、产后3个月

测量方法:

Measure time point of outcome:

at the 42-day and 3-month time points

Measure method:

指标中文名:

爱丁堡抑郁评分

指标类型:

次要指标

Outcome:

Edinburgh Postnatal Depression Scale scores

Type:

Secondary indicator

测量时间点:

产后7天、42天、3个月

测量方法:

Measure time point of outcome:

at 7days,42 days, and 3 months

Measure method:

指标中文名:

静息疼痛和活动性疼痛强度

指标类型:

次要指标

Outcome:

Pain intensity at rest and during activity

Type:

Secondary indicator

测量时间点:

术后24、72小时

测量方法:

Measure time point of outcome:

at 24 hours and 72 hours after surgery

Measure method:

指标中文名:

疼痛强度

指标类型:

次要指标

Outcome:

Pain intensity

Type:

Secondary indicator

测量时间点:

产后7天、42天、3个月

测量方法:

Measure time point of outcome:

at 7days,42 days, and 3 months

Measure method:

指标中文名:

艾氯胺酮或生理盐水输注前后生命体征(血压、心率和脉搏血氧饱和度)的变化

指标类型:

次要指标

Outcome:

Changes in vital signs (blood pressure, heart rate, and pulse oxygen saturation) before and after the esketamine or saline infusion were collected and compared

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿变量,包括出生时性别、体重、出生后1分钟、5分钟的Apgar评分,以及转入新生儿重症监护室的比例

指标类型:

次要指标

Outcome:

Neonatal variables were recorded, such as sex assigned at birth; body weight; Apgar score at 1, 5, and 10 minutes after delivery; and proportion of neonatal intensive care unit transfers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产妇术后首次排气时间、母乳喂养情况和住院时间

指标类型:

次要指标

Outcome:

Time to first flatus after surgery, breastfeeding status, and length of hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

研究期间可能发生的不良事件,如恶心呕吐、头晕、头痛、嗜睡、幻觉、噩梦、眼球震颤等

指标类型:

副作用指标

Outcome:

Adverse events that occurred during the research period included nausea, vomiting, dizziness, headache, drowsiness, hallucinations, nightmares, and nystagmus.

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产后免疫炎症生物标记,如淋巴细胞计数、中性粒细胞/淋巴细胞比、血小板/淋巴细胞比、全身免疫炎症指数等

指标类型:

附加指标

Outcome:

Postpartum Immune-Inflammatory Biomarkers.such as Lymphocyte count, neutrophil-to-lymphocyte ratio , platelet-to-lymphocyte ratio , systemic immune-inflammation index and so on

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院时长

指标类型:

次要指标

Outcome:

Length of postoperative hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产前及产后匹兹堡睡眠质量评分

指标类型:

次要指标

Outcome:

Prenatal and postpartum Pittsburgh Sleep Quality Index (PSQI) scores

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产前爱丁堡抑郁评分

指标类型:

次要指标

Outcome:

Antenatal EPDS scores

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 45 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

随机序列由独立生物统计专家采用R语言(version 4.2.1)的blockrand程序包生成,实施中心分层(按研究中心分层)、区组长度为4的区组随机,按1:1比例将受试者分配至试验组和对照组。随机种子数(set.seed)由系统自动保存并加密,确保序列的不可预测性和可重复性。

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization sequence was generated by an independent biostatistician using R software (version 4.2.1) with the blockrand package, implementing stratified block randomization (stratified by study center with a block size of 4) to allocate participants at a 1:1 ratio to either the experimental or control group. The random seed number (set.seed) was automatically saved and encrypted by the system to ensure unpredictability and reproducibility.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

麻醉护士拆开密封的随机信封并根据分组信息准备药物,术中用药统一配制至20 ml,镇痛泵统一配至100 ml,不做任何标记,隐藏药物配方。麻醉医生及产妇对分组均不知情,术中泵注用药及术后镇痛泵应用由麻醉医生操作应用。

Blinding:

The anesthesia nurse opened the sealed randomization envelope and prepared the study medication according to the group allocation. All intraoperative medications were uniformly prepared to a total volume of 20 ml, while analgesic pump solutions were uniformly prepared to 100 ml. No labeling was applied to conceal the drug formulations. Both the anesthesiologists and the parturients were blinded to the group assignment. The administration of intraoperative pump infusions and postoperative analgesic pump management were performed by the anesthesiologists.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用标准化电子病例记录表(eCRF)进行数据采集。所有研究数据(包括基线资料、干预措施、疗效指标和不良事件)将通过eCRF直接录入,并设置逻辑校验与必填项以确保数据完整性。数据管理采用双人独立录入关键变量,并由监查员定期进行源数据核查以保证数据质量。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study utilizes standardized electronic Case Report Forms (eCRFs) for data collection. All research data (including baseline characteristics, interventions, efficacy endpoints, and adverse events) will be directly entered into the eCRFs, which incorporate logical checks and mandatory fields to ensure data completeness. For data management, we implement dual independent entry for key variables, with regular source data verification by monitors to maintain data quality.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-09-23 17:16:11